Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials

Click to increase image sizeClick to decrease image size

View correction statement:

Correction

Acknowledgments

The authors thank Dr Lee Wade and Dr Muhammad Aziz from the University of Toledo, Ohio for their assistance in creating a search strategy.

Author contributions

GRM conceived the research idea. GRM and KK performed initial search and screening of studies. MG and PB collected all the data. GRM, MB and PG performed data analysis. All authors approved the final version of the manuscript.

Disclosure statement

CW: partner is an employee of Abbvie, Inc.

AG: Amandeep Godara reports consulting for Janssen.

KJ: Kelley Julian reports consulting/advisory for Pfuzer.

DS: Douglas Sborov reports consulting/advisory for Janssen, Sanofi, Pfizer, GlaxoSmithKline, Amgen, and Abbvie.

Data availability statement

Dr. Mohyuddin and Dr. Bindal had full access to data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Correction Statement

This article was originally published with errors, which have now been corrected in the online version. Please see Correction 10.1080/10428194.2023.2215574.

Additional information

Funding

There was no funding for this study.